Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevoflurane versus propofol sedation in COVID-19-related ARDS
2020-001379-34Phase 4Terminated
- Sponsor
- INCLIVA Biomedical Research Institute
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sevoflurane in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by INCLIVA Biomedical Research Institute. Primary endpoints: Change in arterial oxygenation (PaO2/FiO2) on day two and Change in pro-inflammatory cytokine levels. Started Apr 2020; status: terminated.
02
Drugs
sevoflurane
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001379-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001379-34.